417 related articles for article (PubMed ID: 29543715)
1. Utilisation of Chimeric Lyssaviruses to Assess Vaccine Protection against Highly Divergent Lyssaviruses.
Evans JS; Wu G; Selden D; Buczkowski H; Thorne L; Fooks AR; Banyard AC
Viruses; 2018 Mar; 10(3):. PubMed ID: 29543715
[TBL] [Abstract][Full Text] [Related]
2. Antigenic site changes in the rabies virus glycoprotein dictates functionality and neutralizing capability against divergent lyssaviruses.
Evans JS; Selden D; Wu G; Wright E; Horton DL; Fooks AR; Banyard AC
J Gen Virol; 2018 Feb; 99(2):169-180. PubMed ID: 29300155
[TBL] [Abstract][Full Text] [Related]
3. Isolation and Characterization of Cross-Reactive Human Monoclonal Antibodies That Potently Neutralize Australian Bat Lyssavirus Variants and Other Phylogroup 1 Lyssaviruses.
Weir DL; Coggins SA; Vu BK; Coertse J; Yan L; Smith IL; Laing ED; Markotter W; Broder CC; Schaefer BC
Viruses; 2021 Mar; 13(3):. PubMed ID: 33804519
[TBL] [Abstract][Full Text] [Related]
4. Isolation, antigenicity and immunogenicity of Lleida bat lyssavirus.
Banyard AC; Selden D; Wu G; Thorne L; Jennings D; Marston D; Finke S; Freuling CM; Müller T; Echevarría JE; Fooks AR
J Gen Virol; 2018 Dec; 99(12):1590-1599. PubMed ID: 29745870
[TBL] [Abstract][Full Text] [Related]
5. Cross-Protection of Inactivated Rabies Vaccines for Veterinary Use against Bat Lyssaviruses Occurring in Europe.
Servat A; Wasniewski M; Cliquet F
Viruses; 2019 Oct; 11(10):. PubMed ID: 31614675
[TBL] [Abstract][Full Text] [Related]
6. Taiwan Bat Lyssavirus: In Vitro and In Vivo Assessment of the Ability of Rabies Vaccine-Derived Antibodies to Neutralise a Novel Lyssavirus.
Shipley R; Wright E; Smith SP; Selden D; Fooks AR; Banyard AC
Viruses; 2022 Dec; 14(12):. PubMed ID: 36560754
[TBL] [Abstract][Full Text] [Related]
7. Current Rabies Vaccines Do Not Confer Protective Immunity against Divergent Lyssaviruses Circulating in Europe.
Echevarría JE; Banyard AC; McElhinney LM; Fooks AR
Viruses; 2019 Sep; 11(10):. PubMed ID: 31554170
[TBL] [Abstract][Full Text] [Related]
8. Assessing Rabies Vaccine Protection against a Novel Lyssavirus, Kotalahti Bat Lyssavirus.
Shipley R; Wright E; Lean FZX; Selden D; Horton DL; Fooks AR; Banyard AC
Viruses; 2021 May; 13(5):. PubMed ID: 34065574
[TBL] [Abstract][Full Text] [Related]
9. Rabies virus vaccines: is there a need for a pan-lyssavirus vaccine?
Evans JS; Horton DL; Easton AJ; Fooks AR; Banyard AC
Vaccine; 2012 Dec; 30(52):7447-54. PubMed ID: 23084854
[TBL] [Abstract][Full Text] [Related]
10. Cross-neutralization of antibodies induced by vaccination with Purified Chick Embryo Cell Vaccine (PCECV) against different Lyssavirus species.
Malerczyk C; Freuling C; Gniel D; Giesen A; Selhorst T; Müller T
Hum Vaccin Immunother; 2014; 10(10):2799-804. PubMed ID: 25483634
[TBL] [Abstract][Full Text] [Related]
11. Cross-protective and cross-reactive immune responses to recombinant vaccinia viruses expressing full-length lyssavirus glycoprotein genes.
Weyer J; Kuzmin IV; Rupprecht CE; Nel LH
Epidemiol Infect; 2008 May; 136(5):670-8. PubMed ID: 17588277
[TBL] [Abstract][Full Text] [Related]
12. Lyssavirus Vaccine with a Chimeric Glycoprotein Protects across Phylogroups.
Fisher CR; Lowe DE; Smith TG; Yang Y; Hutson CL; Wirblich C; Cingolani G; Schnell MJ
Cell Rep; 2020 Jul; 32(3):107920. PubMed ID: 32697993
[TBL] [Abstract][Full Text] [Related]
13. Ability of rabies vaccine strains to elicit cross-neutralising antibodies.
Brookes SM; Healy DM; Fooks AR
Dev Biol (Basel); 2006; 125():185-93. PubMed ID: 16878476
[TBL] [Abstract][Full Text] [Related]
14. Rabies human diploid cell vaccine elicits cross-neutralising and cross-protecting immune responses against European and Australian bat lyssaviruses.
Brookes SM; Parsons G; Johnson N; McElhinney LM; Fooks AR
Vaccine; 2005 Jul; 23(32):4101-9. PubMed ID: 15964478
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of rabies vaccines in dogs and cats and protection in a mouse model against European bat lyssavirus type 2.
Nokireki T; Jakava-Viljanen M; Virtala AM; Sihvonen L
Acta Vet Scand; 2017 Oct; 59(1):64. PubMed ID: 28969696
[TBL] [Abstract][Full Text] [Related]
16. Vaccines for lyssaviruses other than rabies.
Nel LH
Expert Rev Vaccines; 2005 Aug; 4(4):533-40. PubMed ID: 16117710
[TBL] [Abstract][Full Text] [Related]
17. Cross-Neutralization Activities of Antibodies against 18 Lyssavirus Glycoproteins.
Inoue Y; Kaku Y; Harada M; Ishijima K; Kuroda Y; Tatemoto K; Virhuez-Mendoza M; Nishino A; Yamamoto T; Inoue S; Matsuu A; Maeda K
Jpn J Infect Dis; 2024 May; 77(3):169-173. PubMed ID: 38171846
[TBL] [Abstract][Full Text] [Related]
18. DNA-based immunisation against rabies and rabies-related viruses: towards multivalent vaccines.
Perrin P; Jacob Y; Desmézières E; Tordo N
Dev Biol (Basel); 2000; 104():151-7. PubMed ID: 11713814
[TBL] [Abstract][Full Text] [Related]
19. Protective activity of a murine monoclonal antibody against European bat lyssavirus 1 (EBL1) infection in mice.
Montaño-Hirose JA; Lafage M; Weber P; Badrane H; Tordo N; Lafon M
Vaccine; 1993 Sep; 11(12):1259-66. PubMed ID: 8256507
[TBL] [Abstract][Full Text] [Related]
20. Favourable outcome in a patient bitten by a rabid bat infected with the European bat lyssavirus-1.
Van Gucht S; Verlinde R; Colyn J; Vanderpas J; Vanhoof R; Roels S; Francart A; Brochier B; Suin V
Acta Clin Belg; 2013; 68(1):54-8. PubMed ID: 23627196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
